Kestra Medical Technologies

KMTS · NASDAQ

$28.28−$1.09 (−3.71%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $29.37

KMTS analyst rating

BuyConsensus of 7 analysts over the last 12 months. 71% rate it a buy.

Strong buy0
Buy5
Hold2
Underperform0
Sell0

12-month price target · 9 analysts

Average $30.94 (+9.4% upside)

Low: $28.28
Now: $28.28
High: $33.60

Upgrades and downgrades

The latest rating actions, newest first

KMTS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Evercore ISI Group	Oct 20, 2026	Initiates	Outperform	$34.00	52%
BTIG	Sep 15, 2026	Maintains	Buy	$32.00	56%
BTIG	Sep 2, 2026	Maintains	Buy	$32.00	56%
JP Morgan	Aug 10, 2026	Initiates	Overweight	$30.00	56%
Oppenheimer	Jul 21, 2026	Initiates	Perform	—	44%
BTIG	Jul 15, 2026	Maintains	Buy	$30.00 → $32.00	56%
Goldman Sachs	Apr 9, 2026	Maintains	Neutral	$22.00 → $17.00	48%
BTIG	Apr 7, 2026	Maintains	Buy	$32.00	56%
BTIG	Mar 25, 2026	Maintains	Buy	$32.00	56%
BTIG	Mar 18, 2026	Maintains	Buy	$32.00	56%

The case for and against

Updated Oct 14, 2026

Bull case

Kestra Medical Techs is benefiting from a powerful combination of WCD market expansion, share gains against the incumbent, and commercial execution that is lifting both prescription volumes and revenue conversion through a higher in-network mix and better revenue cycle management. F1Q27 sales rose to $31.0M, up 60% y/y and about $2M above consensus, while gross margin expanded to 56.5% from 45.7% a year earlier, reinforcing the view that the business can scale with improving unit economics. The positive outlook is further supported by an estimated ~15% U.S. market share, approximately $320M of liquidity, and FY27 revenue guidance raised to $141M, suggesting durable momentum despite continued investment in sales, R&D, and infrastructure.

Bear case

Kestra Medical Techs is still in an early commercial ramp, but its valuation already reflects rich expectations at 7.4x forward sales, about 140% above the small-cap MedTech average, leaving limited room for disappointment. Although revenue has nearly doubled to $28.6M and the company has ~15% unit share, it faces meaningful execution, reimbursement, and balance-sheet risks while competing in a duopoly against a far larger incumbent. Patient selection remains difficult in the WCD market, and despite strong wear-time and low false-alarm data, a current US-only footprint, lower revenue per fitting of about $5,400, and reliance on payer mix could constrain profitability and make growth uneven.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.